ERBB2 and breast carcinoma: They acknowledge the importance of distinguishing between a score of 0 or 1+ to determine access to T-DXd based on the DESTINY04 trial criteria; however, they state that there is no evidence to support HER2-low as a new or reproducibly defined subtype of breast cancer.